

**Lack of a Pharmacokinetic Interaction  
between Emtricitabine and  
Tenofovir DF when Co-administered to  
Steady State in Healthy Volunteers**

**M R Blum, J Begley, J Zong, D Hill, N Adda,  
and G Chittick**

**Gilead Sciences, Inc. Durham, NC.**

**43<sup>rd</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy  
September 14-17, 2003  
Chicago, Illinois  
Poster No. A-1621**

# Contact Information

**M. Robert Blum, Ph.D.**

---

**Gilead Sciences, Inc.**

**333 Lakeside Drive**

**Foster City, CA 94404**

**Tel: (650) 574-3000**

**Fax: (650) 578-9260**

# Introduction

---

- **Emtricitabine (Emtriva™, FTC) is a potent new NRTI recently approved in the US for the treatment of HIV infection in adults**
- **As FTC will be combined with tenofovir DF (TDF) in once daily (QD) dosage regimens, a multiple dose study was conducted to evaluate the potential for a pharmacokinetic (PK) interaction when these drugs are administered together**

# Objective

---

- **To evaluate the effect of FTC on steady-state tenofovir pharmacokinetics**
- **To evaluate the effect of TDF on steady-state FTC pharmacokinetics**
- **To evaluate the safety and tolerability when FTC and TDF are administered alone or together for 7 days**

# Methods

---

- **This was a randomized, open-label, 3-period crossover, steady-state drug-drug interaction study in 19 healthy male and female volunteers**
- **Eligible subjects received each of the following three 7-day treatments over a 21-day treatment period (no washout):**
  - **Treatment A: 200 mg FTC QD x 7 days**
  - **Treatment B: 300 mg TDF QD x 7 days**
  - **Treatment C: 200 mg FTC + 300 mg TDF QD x 7 days**
- **Drug was administered 30 min after a standardized breakfast on days 1, 5, 6, and 7 of each treatment period**

# Methods

- Plasma PK assessments were made over a 24-hr dosing interval following the last dose of each treatment
- FTC and tenofovir plasma concentrations were simultaneously analyzed by LC/MS/MS with LOQ of 5 and 10 ng/mL, respectively
- Non-compartmental PK analysis was conducted using WinNonlin™
- A conclusion of no clinically significant difference between the test (FTC+TDF) and reference (FTC alone or TDF alone) treatments was made if the 90% confidence intervals (CIs) of test/reference ratio for the geometric least-squares mean ratio for  $AUC_{ss}$ ,  $C_{max}$  and  $C_{min}$  are each within the range of 0.7 and 1.43

# Results

---

## *Demographics*


- 19 subjects enrolled: 4 female, 15 male
  - mean (range) age 26 yr (19 - 41 yr)
  - mean (range) weight 73.8 kg (61.7 - 94.4 kg)

## *Safety*

- Based on clinical and laboratory evaluations FTC and TDF were well tolerated after multiple dosing alone or together. One subject discontinued for reasons unrelated to the study and one subject for an AE (moderate vomiting episodes while on FTC+TDF)

# Results

Figure 1. Mean FTC Plasma Concentration-time Profiles



# Results

**Table 1. Pharmacokinetic and Statistical Results for FTC When Administered Alone or in Combination with TDF (n=17)**


PK Parameter <sup>1</sup>	FTC Alone	FTC + TDF	Geometric Least Squares Mean Ratio (90% CI)
AUC <sub>ss</sub> (µg·hr/mL)	10.2 (19)	10.7 (11)	1.07 (1.00 - 1.14)
C <sub>max</sub> (µg/mL)	1.8 (22)	1.7 (18)	0.96 (0.87 - 1.06)
C <sub>min</sub> (µg/mL)	0.06 (28)	0.08 (22)	1.20 (1.12 - 1.29)
t <sub>max</sub> (hr)	3.0 (29)	3.0 (20)	N/A
t <sub>1/2</sub> (hr)	10.6 (24)	10.7 (16)	N/A

<sup>1</sup> Mean (%CV)

C<sub>max</sub>= Maximum plasma concentration; C<sub>min</sub>= Minimum plasma concentration;  
t<sub>max</sub>= Time to C<sub>max</sub>; AUC<sub>ss</sub>=Steady-state AUC; t<sub>1/2</sub>= Terminal phase half-life

# Results

Figure 2. Mean Tenofovir Plasma Concentration-time Profiles



# Results

**Table 2. Pharmacokinetic and Statistical Results for Tenofovir When TDF was Administered Alone or in Combination with FTC (n=17)**

PK Parameter <sup>1</sup>	TDF Alone	TDF + FTC	Geometric Least Squares Mean Ratio (90% CI)
AUC <sub>ss</sub> (ng·hr/mL)	2844 (24)	2801 (18)	1.00 (0.92 - 1.09)
C <sub>max</sub> (ng/mL)	279 (21)	288 (22)	1.03 (0.95 - 1.11)
C <sub>min</sub> (ng/mL)	54 (28)	54 (20)	1.02 (0.92 - 1.13)
t <sub>max</sub> (hr)	2.4 (33)	2.4 (38)	N/A
t <sub>1/2</sub> (hr)	15.3 (30)	15.9 (24)	N/A

<sup>1</sup> Mean (%CV)

C<sub>max</sub> = Maximum plasma concentration; C<sub>min</sub> = Minimum plasma concentration;

t<sub>max</sub> = Time to C<sub>max</sub>; AUC<sub>ss</sub> = Steady-state AUC; t<sub>1/2</sub> = Terminal phase half-life

# Results

---

- The 90% CI of  $C_{\max}$ ,  $C_{\min}$  and  $AUC_{ss}$  for FTC + TDF vs. FTC were well within the range of 0.7 to 1.43
- The 90% CI of  $C_{\max}$ ,  $C_{\min}$  and  $AUC_{ss}$  for TDF + FTC vs. TDF were well within the range of 0.7 to 1.43

# Conclusions

---

- **Tenofovir DF had no effect on the pharmacokinetics of emtricitabine**
- **Emtricitabine had no effect on the pharmacokinetics of tenofovir**
- **Safety results from this study were consistent with previous studies conducted in healthy volunteers and raised no new safety issues for emtricitabine or tenofovir DF**